Biopharmaceutical company: Abeona Therapeutics (ABEO) (1989)

Abeona Therapeutics Inc. (NYSE: ABEO) was founded in 1989, formerly PlasmaTech Biopharmaceuticals, Inc., changed to its current name in June 2015, headquartered in Dallas, Texas, with 88 full-time employees. It is a clinical-stage biopharmaceutical the company.

Abeona Therapeutics ABEO Logo

Abeona Therapeutics (ABEO):

Abeona Therapeutics is a biopharmaceutical company that focuses on the development and delivery of gene therapy and plasma-based products to treat serious and life-threatening rare diseases. Abeona Therapeutics’ product candidates mainly include:

  • AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH): Adeno-associated virus (AAV)-based gene therapy for the treatment of San Filippo syndrome (MPS IIIB and IIIA);
  • ABO-201 (scAAV9 CLN3): Gene therapy to treat adolescent Batten disease (JBD);
  • ABO-301 (AAV LK19 FANCC): CRISPR/Cas9-based gene therapy to treat Fanconi anemia (FA) and other rare blood diseases;

In addition, Abeona Therapeutics is developing rare plasma protein therapies, including SDF AlphaT (α-1 protease inhibitor).

In addition, Abeona Therapeutics is also involved in the sale of MuGard and ProctiGard, the former is a treatment for oral wounds, stomatitis, oral ulcers and traumatic ulcers, and the latter is used for the treatment of rectal mucositis and proctitis.

Notify of
Inline Feedbacks
View all Intels

Automobile transportation: Swift Transportation (SWFT), an American transit transportation company-delisting (1966)

Atlas Air Worldwide: Atlas Air Worldwide Holdings (AAWW) (1992)